All In Biotech

Drug Trial Radar · NCT06162728

Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)

A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines and/or Omalizumab, or Who Cannot Tolerate Omalizumab

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

87

Actual

Start

Nov 29, 2023

Primary completion

Jul 8, 2026

Study completion Jul 8, 2026

Sponsor

Lead sponsor
Jasper Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled. The trial is intended to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with H1 antihistamines and omalizumab. Additionally, pharmacokinetic (PK) properties of briquilimab, and other pharmacodynamic (PD) parameters (such as effects on mast cells (MC), serum tryptase levels, and on allergic skin reactivity) will be investigated.

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • BriquilimabDrug

    Subcutaneous Administration

  • PlaceboOther

    Placebo Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability of briquilimabTime frame: From signing the informed consent form (ICF) through end of trial (EOT) visit (up to 48 weeks)

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • Site 118

    Birmingham, Alabama

  • Site 108

    Little Rock, Arkansas

  • Site 105

    San Diego, California

  • Site 113

    Miami, Florida

  • Site 116

    Tampa, Florida

  • Site 109

    Boise, Idaho

  • Site 124

    Springfield, Illinois

  • Site 110

    Indianapolis, Indiana

  • Site 122

    Overland Park, Kansas

  • Site 123

    Lafayette, Louisiana

  • Site 101

    Baltimore, Maryland

  • Site 104

    Chevy Chase, Maryland

  • Site 121

    White Marsh, Maryland

  • Site 103

    Cincinnati, Ohio

  • Site 111

    Murray, Utah

  • Site 115

    Seattle, Washington

  • Site 201

    Berlin, Germany

  • Site 211

    Buxtehude, Germany

  • Site 209

    Dresden, Germany

  • Site 206

    Lübeck, Germany

  • Site 202

    Marburg, Germany

  • Site 210

    München, Germany

  • Site 204

    Münster, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.